We are saddened to share disappointing news from Acadia Pharmaceuticals. The Phase 3 COMPASS clinical trial evaluating intranasal carbetocin (ACP-101) in individuals with PWS did not meet its primary endpoint of reducing hyperphagia. The study also s...
FPWR
Recent Posts
Adults with Prader-Willi syndrome (PWS) can experience earlier-onset changes in health and daily functioning. During a 55‑minute presentation at the United in Hope PWS conference, Dr. Laura de Graaff (Erasmus MC, Rotterdam) discussed practical steps ...
Topics: Adults
A message from Soleno Therapeutics to our PWS Community:
Welcome to an inside look at some of the impactful research taking place to improve the lives of individuals with Prader–Willi syndrome (PWS). In this interview, four FPWR research team members—Theresa Strong, Lauren Schwartz-Roth, Marc Ridilla, and ...
Topics: Research
Each year, the Foundation for Prader-Willi Research (FPWR) recognizes outstanding individuals who have made a profound difference in the lives of those affected by Prader-Willi syndrome. This year, we honored two remarkable leaders for their contribu...
We’re excited to introduce two new members of the FPWR team: Karla Blair and Nicci Peterson! As parents, advocates, and passionate members of the PWS community, Karla and Nicci bring heartfelt commitment and a personal perspective to our work. Their ...
Topics: News
We recently hosted a webinar featuring Dr. Tien Lee and Dr. Manasi Jaiman of Aardvark Therapeutics. They dove into the science and promise behind ARD‑101—an innovative oral medication aimed at curbing hyperphagia in individuals with Prader‑Willi synd...
A published study on the use of guanfacine extended release (GXR) in individuals with Prader-Willi syndrome (PWS) marks an important step forward, showing that guanfacine can improve challenging PWS behaviors, including aggression, skin-picking, and ...
Still United, Still Inspired We're still riding the wave of connection, energy, and inspiration from United in Hope 2025! This incredible event brought together three powerful organizations - the Foundation for Prader-Willi Research (FPWR), the Prade...
